The clinical research on long-term low-dose omeprazole treatment of chronic obstructive pulmonary disease in acute attack
10.3760/cma.j.issn.1008-6706.2018.16.008
- VernacularTitle:小剂量奥美拉唑长期用于慢性阻塞性肺疾病稳定期患者的临床研究
- Author:
Xiaoyan HU
1
Author Information
1. 杭州市大江东医院杭州市第一人民医院集团大江东院区内三科
- Keywords:
Pulmonary disease,chronic obstructive;
Omeprazole;
Comparative study
- From:
Chinese Journal of Primary Medicine and Pharmacy
2018;25(16):2067-2069
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy of the long-term low-dose application of omeprazole for the treatment of chronic obstructive pulmonary disease (COPD) with stability stage,and observe its safety.Methods From July 2013 to August 2014,126 stabilization patients in Dajiang East Hospital of Hangzhou with COPD were selected,and they were randomly divided into Proton pump inhibitor (PPI) therapy group and the control group by random number table method,with 63 cases in each group.The control group patients were given routine therapy,PPI treatment group treated with omeprazole 20mg,one time/day,oral,treatment for 9 months,based on the control group.Frequency of upper respiratory tract infection and the number of COPD exacerbations of the two groups during and after one year treatment were mainly observed,and the adverse reaction of the two groups during the treatment were also observed.Results The frequency of upper respiratory tract infection and the number of COPD exacerbations results of the PPI treatment group during and after one year treatment were (2.04 ± 0.33) times,(2.31 ± 0.50) times and (0.98 ± 0.39) times,(2.26 ± 0.42) times,respectively,which were lower than those of the control group [(2.90 ± 0.31) times,(3.24 ± 0.47) times and (2.41 ± 0.34) times and (3.19 ± 0.38) times],the differences were statistically significant (t =9.33,9.68,10.41,9.19,all P ＜ 0.05).The hospitalized number of the PPI treatment group was (2.30 ± 0.25) times,which was lower than (3.42 ± 0.19) times of the control group,the difference was statistically significant (t =9.04,P ＜ 0.05).There was no statistically significant difference in the adverse reactions between the two groups (P ＞ 0.05).Conclusion The low-dose omeprazole treatment of chronic obstructive pulmonary disease patients can significantly reduce the frequency of upper respiratory tract infection,COPD exacerbations times and the hospital time,and has good security,which has good security.
